Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Integrated BioPharma Inc. (INBP : OTC)

• Company Description    Integrated BioPharma, Inc. is a well-established biopharma company serving the varied needs of the nutraceutical, biotech and pharmaceutical industries. Through a number of wholly owned subsidiaries INB develops, manufactures and distributes, worldwide over 130 products. Number of Employees: 147

• Price / Volume Information    Yesterday's Closing Price: $0.34 Daily Weekly Monthly 20 Day Moving Average: 15,718 shares Shares Outstanding: 30.98 (millions) Market Capitalization: $10.61 (millions) Beta: 0.81 52 Week High: $0.42 52 Week Low: $0.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 18.81% 14.36% 12 Week 18.07% -0.69% Year To Date 3.85% -2.74%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 225 LONG AVENUE BUILDING 15 - HILLSIDE,NJ 07205 USA ph: 888-319-6962 fax: 973-926-1735 investors@ibiopharma.com http://www.ibiopharma.com

• General Corporate Information    Officers Christina Kay - Co-Chief Executive Officer and Director Riva Sheppard - Co-Chief Executive Officer and Director Dina L. Masi - Chief Financial Officer Robert Canarick - Director Damon DeSantis - Director Peer Information Integrated BioPharma Inc. (GSAC) Integrated BioPharma Inc. (CASI) Integrated BioPharma Inc. (ALCD.) Integrated BioPharma Inc. (OMNN) Integrated BioPharma Inc. (CGPI.) Integrated BioPharma Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45811V105 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 09/19/25 Share - Related Items Shares Outstanding: 30.98 Most Recent Split Date: (:1) Beta: 0.81 Market Capitalization: $10.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/19/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 8.56 PEG Ratio: - Price Ratios Price/Book: 0.51 Price/Cash Flow: 7.73 Price / Sales: 0.20 EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 6.09% vs. Previous Quarter: 10.57% ROE 06/30/25 - - 03/31/25 - 6.36 12/31/24 - 4.79 ROA 06/30/25 - - 03/31/25 - 4.84 12/31/24 - 3.54 Current Ratio 06/30/25 - - 03/31/25 - 3.72 12/31/24 - 3.26 Quick Ratio 06/30/25 - - 03/31/25 - 1.70 12/31/24 - 1.27 Operating Margin 06/30/25 - - 03/31/25 - 2.37 12/31/24 - 1.78 Net Margin 06/30/25 - - 03/31/25 - 2.37 12/31/24 - 1.78 Pre-Tax Margin 06/30/25 - - 03/31/25 - 3.55 12/31/24 - 2.79 Book Value 06/30/25 - - 03/31/25 - 0.67 12/31/24 - 0.65 Inventory Turnover 06/30/25 - - 03/31/25 - 4.36 12/31/24 - 4.21 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.17 12/31/24 - 0.00

Powered by Zacks Investment Research ©